Social media

For over 20 years, ICON has supported the development of biosimilars, complex molecules that are highly comparable to their reference biologic drugs. With the large number of biologics losing patent exclusivity over th...

With just two weeks to go, ICON will be at OCT Southern California, booth #26, where our team of experts will introduce you to ICON’s capabilities and explore how biotech and pharma sponsors can accelerate study start-up...

Patient voices matter more than ever in obesity research. Join our upcoming webinar to learn how to combine COAs and digital health technologies to capture the full patient experience. https://ow.ly/mWIK50WLeLf #Clinic...

Early-stage biotech companies face unique #challenges in clinical development. That’s why having partners capable of delivering integrated support - from early development through to trial execution, is crucial. Read th...

Symphony Health, an ICON plc company, are looking forward to Fierce Pharma Week (Sept 8–11) in Philadelphia. Visit us at booth #1320 to explore how our medical affairs, commercial, and promotional solutions help connect...

The next in our UK regulatory environment blog series is out now. In this instalment we discuss the opportunity for interactions with both the MHRA and the National Institute for Health and Care Excellence (NICE). These ...

There are many considerations that set oncology biosimilar development apart from that of novel biologics. Read ICON’s article in Drug Discovery & Development magazine to better prepare for challenges such as developing ...

Clinical data submissions require careful planning, consistency and a strong understanding of agency expectations. This whitepaper explores how regulatory teams can prepare unified materials that meet the requirements of...

Each year, an estimated 400,000 children and adolescents develop cancer. Learn how ICON has been supporting research in #childhoodcancer and other #pediatric diseases. https://ow.ly/VXSx50WOVcN #ChildhoodCancer #Childh...

If your company requires urgent rescue assistance – consider changing CRO. Impossible? Read the full story and learn how the ICON and Sponsor teams had to rapidly prepare for data cuts, while simultaneously transitionin...

Biotechs and pharma companies in Asia Pacific face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is p...

Join ICON experts live to learn how integrating COAs and DHTs in obesity trials supports: • Stronger regulatory alignment • Patient-centered outcomes • Better trial efficiency 📅 Oct 7 | 11am EDT | https://ow.ly/61yJ50...